Thank you for visiting Dumfries & Galloway Health Boards' Prescribing Support Team web site.
The site has been created to act as a central resource for all local drug advice as approved by Dumfries & Galloway Health Boards' Area Drug and Therapeutics Committee.
The ready access to prescribing information will support the safe and cost effective use of drugs in Dumfries & Galloway.
At present we spend £49million on drugs annually; it is therefore imperative that we maximise the health benefits from this investment for the people of Dumfries & Galloway through the use of evidence based medicine.
This document lists the current shortages and where possible advises on an alternative.
This PGD covers the supply of levonorgestrel 1500mcg tablet for use as emergency hormonal contraception by female patients who are aged 13 years or over, provided none of the exclusion criteria apply.
The NHS Dumfries and Galloway Levonorgestrel (LNG) PGD and guidance regarding the supply of Emergency Contraception (EC) have now been updated to reflect recommendations of the Faculty of Sexual and Reproductive Health. https://www.fsrh.org/standards-and-guidance/documents/ceu-clinical-guidance-emergency-contraception-march-2017/ This document provides a summary of the important information that must be considered before supplying Emergency Contraception.
This document authorises the supply of Fusidic Acid Cream 2% by registered pharmacists to patients aged over 2 years old who meet the criteria for inclusion under the terms of the document. The registered pharmacists seeking to supply Fusidic Acid Cream 2% must ensure that all patients have been screened and meet the criteria before supply takes place.
COMMUNITY PHARMACY PUBLIC HEALTH SERVICE SMOKING CESSATION SERVICE – REVISED SERVICE SPECIFICATION 2017 Please note that the NHS Dumfries and Galloway Varenicline PGD differs slightly from the National PGD included in this document. Please See NHS D&G Varenicline PGD.
Following a national tendering process, a new national procurement contract for smoking cessation products has been agreed. This new contract started on 1st March (2017) with this being updated in February 2018 with the withrawal of Johnson & Johnson Please note that this new contract only covers Nicotine Replacement Therapy, with varenicline currently remaining out with the scope of this contract. As a result of this new national contract being implemented, we are required to change our
PATIENT GROUP DIRECTION FOR SUPPLY OF VARENICLINE (CHAMPIX ®) BY AUTHORISED COMMUNITY PHARMACISTS SEPTEMBER 2018